Delcath Systems (NSDQ:DCTH) proposed offering up to $5 million in units and $5 million in pre-funded units this week to fund the company’s clinical and commercial operations. The New York-based company plans to offer 500,000,000 units made up of Series C units with one share of common stock and Series E warrants to buy one share […]
Delcath Systems Inc.
Delcath approves massive reverse split
Delcath Systems (NSDQ:DCTH) said today that shareholders approved a bid to increase the company’s authorized shares of common stock from 500,000,000 to 1,000,000,000. The New York-based oncology group also voted to effect a reverse stock split of Delcath’s common stock at a range of 1-for-100 to 1-for-500. The board of directors have until April 6, 2019 […]
Delcath inks supply deal with Tillomed Laboratories in Europe
Delcath Systems (NSDQ:DCTH) said today that it inked a commercial supply deal with Tillomed Laboratories in Europe. According to the deal, Tillomed Labs is slated to provide Delcath with melphalan – the drug used in Delcath’s hepatic Chemosat delivery system. In Europe, the drug-device combo is approved to treat liver cancer. Get the full story at […]
Delcath closes $5m offering
Delcath Systems (NSDQ:DCTH) has closed a $5 million offering of 212,000 shares of common stock, warrants to buy 38,000,000 shares of common stock and warrants to buy an aggregate of 500,000 shares of common stock. The New York-based company priced the offering at 2¢ per unit. Each unit was composed of one share of common stock […]
Delcath touts 500th commercial Chemosat treatment in Europe
Delcath Systems (NSDQ:DCTH) said today that doctors in Europe performed the 500th percutaneous hepatic perfusion therapy treatment using Delcath’s Chemosat delivery system. The drug-device combo has been available in certain European markets since 2012. Get the full story at our sister site, Drug Delivery Business News.
Shares in Delcath fall after losses grow in Q3
Shares in Delcath Systems (NSDQ:DCTHD) crashed today after the company posted its third quarter results, revealing that the company’s net losses have grown dramatically quarter-over-quarter. The N.Y.-based company posted a net loss of -$12.6 million on sales of $684,000 for the 3 months ended Sept. 30, for sales growth of 57% compared with the same period last year. […]
Delcath plans for 1-for-350 reverse split
Delcath Systems (NSDQ:DCTH) said today that it is preparing for a 1-for-350 reverse stock split, which is set to take effect on Nov. 6. According to the terms of the reverse split, Delcath’s common stock will trade under a new symbol – DCTHD – for twenty days and then revert back to its old symbol, DCTH. […]
Delcath deal with investors raises $500k, clears path for reverse split
Delcath Systems (NSDQ:DCTH) and a group of investors made an end run around the company’s shareholders with a deal that paves the way for the reverse split that stockowners have twice shot down. “Together with our Board of Directors, we are taking these actions in the best interests of all shareholders. Regaining access to equity capital will […]
CIRSE 2017 Round-up: Delcath touts second-gen hemofiltration system in percutaneous hepatic perfusion
Delcath Systems (NSDQ:DCTH) touted data today from a study of its second-generation hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan hydrochloride. The New York-based company presented the results from its study at the Cardiology and Interventional Radiology of Europe annual meeting in Copenhagen, Denmark. The investigational product, an injectable melphalan hydrochloride for use with […]
Delcath readies for reverse stock split
Delcath Systems (NSDQ:DCTH) said today that it inked a deal to extinguish its 2016 convertible notes with the unnamed holder of the majority of the notes. But the agreement is contingent upon the company effecting a reverse stock split – a move that shareholders voted down in June. The company’s board urged shareholders to this time […]
Delcath raises $2m in Series B stock sale
Delcath Systems (NSDQ:DCTH) has raised $2 million after selling 2,360 shares of Series B preferred stock at $1,000 per share to unnamed institutional investors, according to a regulatory filing. The company wrote that it plans to use the proceeds for general corporate purposes. Get the full story at our sister site, Drug Delivery Business News.
